Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

Apr 08 2016 Pharmaceuticals

Market Ready to Adopt Long-Acting Buprenorphine As Opioid Treatment Option

Research Question:Will long-acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Companies: ALKS, BDSI, HRTX, LON:INDV, STO:CAMX, STO:ORX, TLV:TEVA, TSX:GUD, TTNP By: David Franklin Click here to download the report (.pdf)   Summary of Findings Long-acting implantable and injectable buprenorphine is expected to become an important tool and gain a significant foothold […]

Read more...

Teleflex Idea Proposal

Teleflex Idea Proposal

Will hospitals continue to accept price hikes for Teleflex’s vascular products when competitors are dropping prices? Report Available: April 20, 2016   Blueshift’s initial research shows TFX has benefited from a broad healthcare/medical device product line, a deep product pipeline, and the ability to command higher prices than the competition. With the healthcare spending growth […]

Read more...

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Early Warning for ZLTQ’s CoolSculpting: CYNO’s SculpSure Could Cut into Next Year’s Share

Research Question: Can Zeltiq’s CoolSculpting system continue to fend off competitors with similar or superior body contouring products? Companies: AGN, CUTR, CYNO, ELOS, LMNS, NUS, TSE:VRX, ZLTQ By: David Franklin Click here to download the report (.pdf)   Summary of Findings Zeltiq Aesthetics Inc.’s (ZLTQ) CoolSculpting now faces competition from Cynosure Inc.’s (CYNO) recently approved SculpSure […]

Read more...

Novadaq’s SPY Elite: A Solid Technology Facing Moderate Growth Due to Adoption Challenges

Research Question: Will Novadaq’s SPY Elite be widely adopted and drive company growth in 2016? Companies: EPA:MKEA, ETR:SIE, ISRG, NVDQ, TYO:6965 By: David Franklin Click here to download the report (.pdf)   Summary of Findings The medical community considers Novadaq Technologies Inc. (NVDQ) to have innovative and interesting tissue perfusion assessment technology in its product line. […]

Read more...

Zeltiq Aesthetics Idea Proposal (ZLTQ)

Zeltiq Aesthetics Idea Proposal (ZLTQ)

Research Question: Can Zeltiq Aesthetics’ CoolSculpting system continue to fend off competitors with similar or superior body contouring products? Report Available: January 15, 2016   Blueshift’s initial research shows ZLTQ investing heavily in sales and marketing, with strong sales results from its CoolSculpting body contouring system. Competing products are coming on strong and some appear to […]

Read more...

Novadaq Technologies Idea Proposal

Novadaq Technologies Idea Proposal

Research Question: Will Novadaq’s SPY Elite be widely adopted and drive the company’s growth in 2016? Report Available: Nov. 24, 2015   Blueshift’s initial research shows NVDQ’s sales momentum increasing now that its technology is transitioning into the adoption phase. But its SPY fluorescence imaging systems could still be years away from achieving angiography gold standard status, […]

Read more...

Blockbuster Sales Not in Store for Depomed’s Nucynta

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as the company takes on OxyContin among acute pain patients and Lyrica and Cymbalta in neuropathic pain patients? Companies: DEPO, HZNP, JNJ, LLY, PFE, TSE:ENL By: David Franklin Click here to download the report (.pdf)   Summary of Findings Depomed Inc.’s (DEPO) Nucynta and Nucynta […]

Read more...

Abiomed’s Impella Will Drive Growth But Not at Projected 40%

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Companies: ABMD, STJ By: David Franklin Click here to download the report (.pdf)   Summary of Findings The Impella Platform is expected to drive growth for Abiomed Inc. (ABMD) but not at corporate’s 2020 projected sales rate of $1.2 billion to $1.8 billion, […]

Read more...

Depomed Idea Proposal (DEPO)

Depomed Idea Proposal (DEPO)

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015   Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]

Read more...